Dr Benjamin Lewis Hechler, DDS, MD | |
40 Duke Medicine Cir # 1f, Durham, NC 27710-1511 | |
(919) 660-0320 | |
Not Available |
Full Name | Dr Benjamin Lewis Hechler |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 40 Duke Medicine Cir # 1f, Durham, North Carolina |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053751594 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Benjamin Lewis Hechler, DDS, MD 2100 Erwin Rd # Dumc3974, Durham, NC 27705-3941 Ph: (913) 940-2700 | Dr Benjamin Lewis Hechler, DDS, MD 40 Duke Medicine Cir # 1f, Durham, NC 27710-1511 Ph: (919) 660-0320 |
News Archive
China PharmaHub Corp., which recently merged with World Wide Relics and, effective August 23, 2010, changed its name from World Wide Relics, Inc. to China PharmaHub Corp., announced today that effective Tuesday, September 7, 2010, its stock shall begin trading under the symbol "CPHB."
Women with interruptions in health insurance coverage or with low income levels had a significantly increased likelihood of failing to receive breast cancer care that is in concordance with recommended treatment guidelines, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.
Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis.
A paper published today, "Financing translation: Analysis of the NCATS rare-diseases portfolio" in Science Translational Medicine, demonstrates the potential of a new financing technique to reduce the risk associated with investing in the treatment of new diseases and potentially unlock new levels of funding for developing so-called "orphan" drugs.
› Verified 7 days ago